Healthcare Industry News: HSMN NewsFeed

Biopharmaceuticals Personnel

 News Release - April 19, 2018

Management Change in Moberg Pharma

STOCKHOLM, April 19th, 2018 -- (Healthcare Sales & Marketing Network) -- Moberg Pharma AB (OMX: MOB) announces that Kjell Rensfeldt, VP Research and Development, will retire in the fall but remain with the company part-time as Senior Adviser.

On October 1st 2018, Kjell Rensfeldt, VP Research and Development, will retire from Moberg Pharma, but remain with the company in a part-time role as Senior Adviser. The process of finding his replacement has started.

"With extensive knowledge and experience, Kjell has contributed to the evolution of Moberg Pharma, especially through the development of Kerasal NailŪ and MOB-015, where he has been instrumental. I've had the pleasure of working with Kjell since 2007 and I am highly grateful for his efforts over the years. I look forward to continuing our collaboration in his role as Senior Advisor to the company", says Peter Wolpert, CEO Moberg Pharma.

About this information

This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 9.30 a.m. CET on April 19th, 2018.

Source: Moberg Pharma

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

RepFinder 2 - Find Great Medical Independent Sales Reps without recruiter fees.
RepFinder 2 - available on the Apple App Store for iPhone and iPad.